a year ago

Qureight Secures $8.5M Series A to Revolutionize Drug Development with AI-Powered Clinical Trials

  • Qureight, a UK-based biotech company, has raised $8.5 million in a Series A funding round

  • The company uses AI to streamline the drug development process by making clinical trials more efficient

  • Their platform aggregates patient data, allowing for faster and more informed decisions regarding drug efficacy

  • The funding will be used to expand their operations, improve their AI models, and potentially enable virtual clinical trials in the future.

      • ProblemHealthcare

      "Drug development is slow and expensive, with clinical trials being a major bottleneck. Traditional clinical trials are time-consuming and inefficient due to the difficulty of collecting and analyzing data from multiple sources."

      Solution

      "Qureight's AI platform helps speed up clinical trials by centralizing data from different sources, allowing for faster and more efficient analysis. This allows researchers to make better decisions about drug development and potentially reduce the time and cost of bringing new drugs to market."

      Covered on